Clinical Trials Browser

Unknown × Triple Negative Breast Neoplasms × 130-nm albumin-bound paclitaxel × Clear all

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

98 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

Phase 2 Unknown

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

Phase 2 Unknown

100 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Phase 2 Unknown

46 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05068141 2021-10-15

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Phase 2 Unknown

79 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04907344 2021-05-28

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2/3 Unknown

420 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

FUTURE-SUPER

SPARK

MARIO-3

NeoPATH

FUTURE

HIFU

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)